SW033291 is a potent small molecule that enhances the activity of prostaglandin E2 (PGE2) by inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme responsible for PGE2 degradation. This action leads to increased levels of PGE2, which plays a key role in tissue regeneration and stem cell expansion. One major application of SW033291 is in regenerative medicine, particularly in accelerating hematopoietic stem cell (HSC) recovery after bone marrow transplantation. It has shown promise in reducing the time to neutrophil and platelet engraftment in preclinical models, which could significantly improve outcomes in patients undergoing chemotherapy or stem cell transplants. It is also being explored for use in promoting intestinal repair and recovery from colitis due to PGE2’s role in maintaining epithelial integrity and reducing inflammation in the gut. Additionally, its ability to modulate stem cell activity makes it a candidate for ex vivo expansion of stem cells for transplantation purposes. Due to its regenerative properties, SW033291 is under investigation for potential applications in wound healing, liver regeneration, and other conditions where tissue repair is critical.